Financial Statements Schedule I (Tables)

12 Months Ended

Dec. 31, 2022

Condensed Financial Information Disclosure [Abstract]

Condensed Balance Sheets

	December 31,
	2022	2021
	$	$
Assets
Current assets:
Cash and cash equivalents	944,649	591,842
Short-term investments	—	445,000
Prepayments and other current assets	10,203	2,364
Total current assets	954,852	1,039,206
Investment in subsidiaries	93,363	341,980
Total assets	1,048,215	1,381,186
Liabilities and shareholders’ equity
Liabilities
Current liabilities:
Other current liabilities	2,620	996
Total current liabilities	2,620	996
Deferred income	—	234
Total liabilities	2,620	1,230
Shareholders’ equity
Ordinary shares (par value of $0.000006 per share; 5,000,000,000 shares authorized, 962,455,850 and 955,363,980 shares issued as of December 31, 2022 and 2021, respectively; 960,219,570 and 954,981,050 shares issued and outstanding as of December 31, 2022 and 2021, respectively)	6	6
Additional paid-in capital	2,893,120	2,825,948
Accumulated deficit	(1,861,360)	(1,418,074)
Accumulated other comprehensive income (loss)	25,685	(23,645)
Treasury stock	(11,856)	(4,279)
Total shareholders’ equity	1,045,595	1,379,956
Total liabilities and shareholders’ equity	1,048,215	1,381,186

Condensed Statements of Operations and Comprehensive Loss

	Year Ended December 31,
	2022	2021	2020
	$	$	$
Operating Expenses:
Research and development	(178)	(6)	(437)
General and administrative	(19,773)	(12,074)	(7,345)
Loss from operations	(19,951)	(12,080)	(7,782)
Interest income	12,857	1,881	4,899
Other (expenses) income, net	(8,678)	(18,173)	312
Profit (Loss) before income tax and equity in loss of subsidiaries	(15,772)	(28,372)	(2,571)
Equity in loss of subsidiaries	(427,514)	(676,099)	(266,334)
Income tax expense	—	—	—
Net loss	(443,286)	(704,471)	(268,905)
Other comprehensive income (loss), net of tax of nil:
Foreign currency translation adjustment	49,330	(9,121)	(19,144)
Comprehensive loss	(393,956)	(713,592)	(288,049)

Condensed Statements of Cash Flows

	Year Ended December 31,
	2022	2021	2020
	$	$	$
Cash flows from operating activities:
Net loss	(443,286)	(704,471)	(268,905)
Adjustments to reconcile net loss to net cash provided by operating activities:
Amortization of deferred income	(234)	(312)	(312)
Share based compensation	3,724	3,435	3,025
Equity in loss of subsidiaries	427,514	676,099	266,334
Loss from fair value changes of equity investment of readily determinable fair value	8,952	14,617	—
Changes in operating assets and liabilities:
Prepayments and other current assets	(7,839)	(439)	2,253
Other current liabilities	1,648	(376)	738
Net cash provided by (used in) operating activities	(9,521)	(11,447)	3,133
Cash flows from investing activities:
Purchases of short-term investments	(260,274)	(445,000)	(949,161)
Proceeds from maturity of short-term investments	705,274	743,902	405,000
Purchase of investment in equity investee	—	(30,000)	—
Investment in subsidiaries	(80,942)	(884,342)	(256,097)
Net cash provided by (used in) investing activities	364,058	(615,440)	(800,258)
Cash flows from financing activities:
Proceeds from exercises of stock options	5,870	7,418	6,664
Proceeds from issuance of ordinary shares upon public offerings	—	818,875	1,137,683
Payment of public offering costs	—	(1,692)	(4,541)
Employee taxes paid related to settlement of equity awards	(7,600)	(4,253)	—
Net cash provided by (used in) financing activities	(1,730)	820,348	1,139,806
Effect of foreign exchange rate changes on cash and cash equivalent	—	773	(515)
Net increase in cash and cash equivalents	352,807	194,234	342,166
Cash and cash equivalents-beginning of the year	591,842	397,608	55,442
Cash and cash equivalents-end of the year	944,649	591,842	397,608